BRAF V600 Mutation clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.
Our lead scientists for BRAF V600 Mutation research studies include Katy Tsai, M.D..